Wendy D. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wendy D. Smith has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bradley J. Atkinson
University of Texas M. D. Anderson Cancer Center
1 shared publication - David M. Crowther
David M. Crowther, UT MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0377, Houston, TX 77030, USA
1 shared publication Erin M. Timpe
Drug Information and Wellness Center, School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville
1 shared publication- John C. Araujo
The University of Texas MD Anderson Cancer Center, Houston, TX
1 shared publication Julie P. Karpinski
Drug Information and Wellness Center
1 shared publication- Laura Ng
Division of Pharmacy, MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX 77030, USA
1 shared publication
Latest Publications
- Open Access
The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T
Sipuleucel-T is an immunotherapy indicated for the treatment of metastatic prostate cancer. It offers a new mechanism to treat prostate cancer without the side effects of hormone therapies and chemotherapies. In previous studies sipuleucel-T did not delay disease progression, but demonstrated an overall survival benefit compared to placebo. While clinical trials have evaluated the effects of sipuleucel-T on overall survival and progression, more studies are needed to evaluate its effectiveness and role in the management of prostate cancer. The objective of this study is to identify the incidence and possible predictors for disease progression in patients receiving sipuleucel-T. A retrospective review of patients who received sipuleucel-T between 1 September 2010 and 11 October 2011 was conducted (n = 36). Patients who changed therapy or died within 120 days were classified as experiencing rapid progression. Potential predictors of rapid progression were examined using logistic regression. Seven patients met criteria for rapid progression. Progression occurred in 72.2% of all patients. The median days to progression was 158. No significant predictors of rapid progression were identified. Currently no predictors have been found to be associated with rapid progression in prostate cancer patients on sipuleucel-T.
Open AccessThe Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T
Sipuleucel-T is an immunotherapy indicated for the treatment of metastatic prostate cancer. It offers a new mechanism to treat prostate cancer without the side effects of hormone therapies and chemotherapies. In previous studies sipuleucel-T did not delay disease progression, but demonstrated an overall survival benefit compared to placebo. While clinical trials have evaluated the effects of sipuleucel-T on overall survival and progression, more studies are needed to evaluate its effectiveness and role in the management of prostate cancer. The objective of this study is to identify the incidence and possible predictors for disease progression in patients receiving sipuleucel-T. A retrospective review of patients who received sipuleucel-T between 1 September 2010 and 11 October 2011 was conducted (n = 36). Patients who changed therapy or died within 120 days were classified as experiencing rapid progression. Potential predictors of rapid progression were examined using logistic regression. Seven patients met criteria for rapid progression. Progression occurred in 72.2% of all patients. The median days to progression was 158. No significant predictors of rapid progression were identified. Currently no predictors have been found to be associated with rapid progression in prostate cancer patients on sipuleucel-T.
- 1 December 2012
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 69 (23) , 2089-2093
Changes to medication-use processes after overdose of U-500 regular insulin
Purpose Modifications made to medication-use processes after an overdose of U-500 regular insulin are described. Summary After a medication error occurred with U-500 regular insulin, a multidisciplinary team of physicians, nurses, advanced-practice nurses, and pharmacists was created to review and improve the ordering, dispensing, and administration processes associated with U-500 regular insulin. The group determined that current safety practices for managing insulin were inadequate. New safety processes specific to U-500 regular insulin were developed and implemented. Vials of U-500 regular insulin are no longer dispensed to nursing units and are stored only in the pharmacy and separated from other insulins. The ordering of U-500 regular insulin is limited to the endocrinology service, and all orders are written using a specialized U-500 regular insulin order set. The option for i.v. administration for U-500 regular insulin was removed from the pharmacy order-entry system; thus, only the subcutaneous route is entered by the pharmacist. In addition, patient-specific doses of U-500 regular insulin are prepared in the pharmacy using only tuberculin syringes that require a double check by two pharmacists. These syringes are delivered to patient care areas in a bag distinguishing the medication as “high alert.” One last safety check involving a two-nurse check at the bedside to confirm correct medication administration is performed. Lastly, patient education material specifically for U-500 regular insulin is available online. Conclusion A multidisciplinary team recommended modifications to the medication-use system regarding U-500 regular insulin after review of a medication error. No errors involving U-500 regular insulin have been reported since implementation of the changes.
- 1 December 2012
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 69 (23) , 2089-2093
Changes to medication-use processes after overdose of U-500 regular insulin
Purpose Modifications made to medication-use processes after an overdose of U-500 regular insulin are described. Summary After a medication error occurred with U-500 regular insulin, a multidisciplinary team of physicians, nurses, advanced-practice nurses, and pharmacists was created to review and improve the ordering, dispensing, and administration processes associated with U-500 regular insulin. The group determined that current safety practices for managing insulin were inadequate. New safety processes specific to U-500 regular insulin were developed and implemented. Vials of U-500 regular insulin are no longer dispensed to nursing units and are stored only in the pharmacy and separated from other insulins. The ordering of U-500 regular insulin is limited to the endocrinology service, and all orders are written using a specialized U-500 regular insulin order set. The option for i.v. administration for U-500 regular insulin was removed from the pharmacy order-entry system; thus, only the subcutaneous route is entered by the pharmacist. In addition, patient-specific doses of U-500 regular insulin are prepared in the pharmacy using only tuberculin syringes that require a double check by two pharmacists. These syringes are delivered to patient care areas in a bag distinguishing the medication as “high alert.” One last safety check involving a two-nurse check at the bedside to confirm correct medication administration is performed. Lastly, patient education material specifically for U-500 regular insulin is available online. Conclusion A multidisciplinary team recommended modifications to the medication-use system regarding U-500 regular insulin after review of a medication error. No errors involving U-500 regular insulin have been reported since implementation of the changes.
- 1 August 2009
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 66 (15) , 1369-1375
Evaluation of seven i.v. drug compatibility references by using requests from a drug information center
Purpose. The scope of coverage and clinical performance of i.v. drug compatibility references were evaluated for drug pairs.
- 1 August 2009
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 66 (15) , 1369-1375
Evaluation of seven i.v. drug compatibility references by using requests from a drug information center
Purpose. The scope of coverage and clinical performance of i.v. drug compatibility references were evaluated for drug pairs.